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Introduction
Desmoplastic small round cell tumour (DSRCT) is
an extremely rare and aggressive malignancy affecting
most of the times young males in their second and
third decades of life (1). This tumour, first described in
1989, is a member of the group of small round blue
cell tumours (2) and involves mainly the abdomen and
the pelvis, although thoracic, intracranial and parate-
sticular primary sites have been described (3). It usual-
ly has the tendency to spread along the peritoneum
and mesothelial lined-surface, so that organ involve-
ment is only a secondary phenomenon (4).
Complete resection is generally difficult to obtain
due to multiple foci and dissemination. A standard
treatment protocol has not been well established. As-
sociation of surgery and chemotherapy seems to be the
best potential treatment (5).
This work present a case of DSRCT with no recur-
rence after 12 months following complete resection of
the tumour and postoperative multi-agent chemothe-
rapy and underscore the main features of this disease.
Case report
R.S., 17 yeas old male patient, presented in Emergency Room
for stabbing left hypochondrium pain. His past medical history
did not show any significant disease; two day before he had been
accidentally hit on the left thorax. After this minor trauma, the pa-
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tient had pain while breathing and after two days this pain migra-
te in the left hypochondrium. The patients also declared a 10 kg
weight loss in 4-5 month that was explained by him as the conse-
quence of a diet.
On physical examination the abdomen was soft, not tender,
and a 10 cm mass could be palpated in left hypochondrium
without evoking pain. Laboratory tests were all normal. An ultra-
sound scan showed a 13 cm hypoechogenic mass in left hypochon-
drium with some pleuric fluid on both sides. A CT scan confirmed
the presence of the voluminous subdiaphragmatic round mass,
with a solid content alternated to some areas of colliquation and
some of calcification, that reached the inferior pole of the spleen
and dislocated the stomach, the pancreas and the left colon. This
mass was very close to the liver and infiltrated the splenic vascular
pedicle (Fig. 1).
At laparotomy a voluminous neoplasm, arising from the retro-
peritoneum, that infiltrates the left side of the gastric body and an-
trum, the left lobe of the liver and the diaphragm, was evident
(Fig. 2). A complete excision of the mass was performed en bloc
with splenectomy, longitudinal partial gastrectomy with a GEEA
80, regulated left liver lobectomy and partial resection of the
diaphragm. The diaphragm was reconstructed by means of a pat-
ch of Gore-Tex. 
Postoperative period was uneventful and the patient was di-
scharged at VII day.
The mascroscopic report of the pathologist showed a
18x20x14 cm ovoidal mass of white-gray hard tissue with a granu-
lose surface, and a soft and necrotic core. This mass infiltrates the
stomach and neoplastic nodules were present in the omentum, the
capsule of spleen and the liver, while the parenchyma was free of
any infiltration. 
The histological examination confirmed the presence of a high
malignancy grade desmoplastic small round cell tumor of the retro-
peritoneum, with intraperitoneal multinodular dissemination. One
lymph node of the lesser curvature resulted metastatic. Immunohy-
stochemistry showed a marked positivity to vimentine, desmin and
neuron-specific enolase. A positivity for cytocheratin was present in
single cells. A complete negativity was observed for miogenin,
smooth muscle cell actin, protein S-100, synaptophysin. 
The patient underwent postoperative chemotherapy using the
IVADo regimen (Ifosfamide 3 g/m2 day 1 and 2; Vincristine 1,5
mg/m2 day 1; Actinomycin D 1,5 mg/m2 day 1; and Doxorubicin
30 mg/m2 day 1 and 2). He is alive and free of recurrence at 12
months follow-up.
Discussion
First described by Gerald and Rosai (6), DRSCT
has distinct clinical, histological and polyphenotypic
immunohistochemical features (7-9). The distinctive
pathological finding of DRSCT is a nesting pattern of
cellular growth within dense desmoplastic stroma and
immunohistochemical coexpression of epithelial, mu-
scle and neural markers (6, 8, 10). Genetic expression
observed consistently in DRSCT reveals a unique re-
ciprocal translocation - (t11;22)(p13;q11 or q12) - as
Fig. 2 - Laparotomy showing the mass infiltrating the
stomach and the liver.
Fig. 1 - CT scan of the mass.
the result of fusion of exon 7 of Ewing’s sarcoma gene
(EWS) on chromosome 22 with exon 8 of Wilm’s tu-
mour suppressor gene (WT1) on chromosome 11
(11).
DRSCT usually occurs in young male with a ma-
le-female ratio of 5 to 1 and a mean age of 20 years (2,
8). The main features of this tumour is the striking
predilection for serosal surfaces, mainly the perito-
neum but also the pleura, and the tunica vaginalis of
the testis, with only minor or no organ involvement.
(7, 12 ) The most common site of presentation is the
pelvis (62% of the cases) followed by spreading widely
on the peritoneal surface (42%) (6, 8).
The most frequent presenting symptoms and signs
reported in literature, such as abdominal pain , disten-
sion and a palpable abdomen, are non-specific and
non-diagnostic (4). Many authors underscore that
DRSCT present as a diffuse process within the abdo-
men without any apparent organ of origin (3, 13).
Differently from extra-abdominal presentation, where
this tumour is usually less extensive, in the abdomen
and in the pelvis typically it presents in an advanced
stage with a bulky primary mass and satellite nodules
that fill the peritoneal cavity, as in our case (14). The-
se large masses may simulate ovarian tumours or cysts
in women and may also give urinary symptoms (8, 9,
12). Often lymph node, liver and lung metastasis
coexist at the time of diagnosis (3).
Because of the tendency of DRSCT to involve the
peritoneal and serosal surfaces with desmoplastic im-
plant during the course of the disease, several patients
may develop intestinal obstruction as a first manifesta-
tion, which will require either a debulking with inte-
stinal resection or palliative bypass. Therefore it is im-
portant to consider DSCRT as a possible diagnosis
when a young man presents with non-specific abdo-
minal symptoms and evidence of disseminated intra -
and extra-abdominal malignancy (4).
The most common diagnostic tool is CT scan.
This shows a characteristic pattern of multiple intra-
abdominal masses without apparent relationship with
primary organs (11). An open biopsy may be useful
for an accurate diagnosis so that the pattern of cellular
nests can be seen. It enables histochemical tests to be
carried out and may be used even in case of recurren-
ce (11). Laparoscopy has also recently been used for
biopsy of these tumours (11, 15).
Our case showed another distinctive feature of
DRSCT, i.e. immunohistochemical polyphenotipic
profile (cytocheratin, vimentine and neuron-specific
enolase) suggestive of tripartite differentiation (epithe-
lial, mesenchymal and neuroectodermal) (6). 
The disease spread pattern reveals the predilection
of these tumours to metastasise through both lympha-
tic and haematogenous routes, so combined surgery
and chemotherapy is needed for the management of
this disease. The effect of complete resection of disse-
minated tumours on survival is still unknown because
of the rarity of achieving it at operation. Some authors
(16) reported a median survival of 20 months in 4 pa-
tients with complete resection of tumors compared
with 11 months in 3 cases without complete resection.
Significantly, long-term survivors, including one pa-
tient who survived for 101 months, have been treated
with surgery and multi-agent chemotherapy.
Since DSRCT is a highly aggressive and progressi-
ve malignancy, postoperative adjuvant chemotherapy
should be initiated as soon as possible. Farhat et al.
(17) reccomended that PAVEP (Cyclophosphamide
300 mg/m2, day 1-3; Etoposide 75 mg/m2, day 1-3;
Doxorubicin 40 mg/m2, day 1; Cisplatin 100 mg/m2,
day 4) should be the first line drug for treating
DSRCT after reviewing 8 cases with complete remis-
sion. However, considering the severe and life-threate-
ning side effects, such grade four neutropenia, and un-
certainty of the therapeutic results of PAVEP regimen,
other safer and effective chemotherapeutic agents
should be considered before it.
5-FU is well-known as a chemotherapeutic agent
and a radioactive sensitizer broadly used for gastroin-
testinal tract cancers and disseminated intra-abdomi-
nal metastatic adenocarcinomas. Gerald et al. (8) re-
ported a successful application of 5-FU in treating in-
tra-abdominal DSRCT. Kretschmar et al (3) also re-
ported 60% responsive rate to this chemotherapeutic
agent. So it is reasonable to start chemotheraphy with
5-FU especially in patient that had post-operative pro-
blems due to the extent of the resection and may not
tolerate the adverse effect of the PAVEP regimen.
Another alkylator-based chemotherapy protocol
named P6 (Cyclophosphamide, Doxorubicin, Vincri-
stine, Ifosfamide, and Etoposide) was used to treat
DSRCT but it only improved the progression-free sur-
vival without significant survival benefit (18).
The IVADo regimen (Ifosfamide 3 g/m2 day 1 and
2; Vincristine 1,5 mg/m2 day 1; Actinomycin D 1,5
mg/m2 day 1; and Doxorubicin 30 mg/m2 day 1 and
2) used in our case proved to be an intensive regimen
that is very effective against pediatric sarcomas, whe-
reas toxicity is manageable by expert oncologist teams,
even if its role in the treatment of DSRCT is still to be
well established with randomised trials (19).
Other authors recommended perioperative intra-
peritoneal chemotherapy when treating DSRCT pa-
tients, but no evidence of prolonged survival was ob-
served (16).
Radiotherapy can be applied preoperatively only in
unresectable desmoid tumours and postoperatively for
the control of local relapse in patients with microsco-
pic residual disease following resection. The indication
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of radiotherapy is still debated due to its late sequelae
such as fibrosis and radiation-induced secondary mali-
gnancy (20). 
The influence of other salvage therapies, such as
immunotherapy or bone marrow ablation, is still un-
determined even if preliminary results seems encoura-
ging (21).
Conclusion
The prognosis of DSRCT is dismal with a mean
survival of 1.5-2.5 years since the wide spread of the
tumor makes radical resection difficult to achieve, and
chemotherapeutic agents are often only temporarily
effective in treating this disease (4).
No consensus has been reached concerning the op-
timal strategy for managing DRSCT. Furthermore,
because of the heterogeneity of the therapeutic moda-
lities utilized, it is difficult to compare the efficacy and
effectiveness of various regimens. However the current
literature suggests that an aggressive approach invol-
ving total macroscopic excision of the tumour combi-
ned with chemotherapy and radiation may offer the
best opportunity for disease control and disease free
survival.
370
F. Talarico et al.
1. Leuschner I, Radig K, Harms D. Desmoplastic small round
cell tumour. Semin Diagn Pathol 1996; 20:406-412.
2. Gerald WL, Ladanyi M, de Alava E, Cuatrecasas M, Kushner
BH, La Quaglia MP, Rosai J. Clinical, pathologic, and mole-
cular spectrum of tumors associated with (t11;22)(p13;q12):
desmoplastic small round-cell tumor and its variants. J Clin
Oncol 1998;16:3028-36.
3. Kretschmar CS, Colbach C, Bhan I, Crombleholme TM. De-
smoplastic small cell tumor: a report of three cases and a re-
view of the literature. J Pediatr Haematol Oncol 1996; 18:
293-298.
4. Hassan I, Shyynan R, Donohue JH, Edmonson JH, Gunder-
son LL, Moir CR, Arndt CAS, Nascimento AG, Que FG. In-
tra-abdominal desmoplastic small round cell tumours. A dia-
gnostic and therapeutic challenge. Cancer 2005;104:1264-70.
5. Chang-Cheng C, Jun-Te H, Jeng-Hwei T, Tsann-Long H,
Han-Ming C, Yi-Yin J. Combined resection and multi-agent
adjuvant chemotherapy for desmoplastic small round cell tu-
mor arising in the abdominal cavity: report of a case. World J
Gastroenterol 2006;12:800-3.
6. Gerald WL, Rosai J. Case 2. Desmoplastic small cell tumor
with divergent differentiation. Pediatr Pathol 1989;9:177-83.
7. Cummings OW, Ulbright TM, Young RH, Del Tos AP, Flet-
cher CD, Hull MT. Desmoplastic small round cell tumors of
the paratesticular region. A report of six cases. Am J Surg
Pathol 1997;21:219-25.
8. Gerald WL, Miller HK, Battifora H, Miettinen M, Silva EG,
Rosai J. Intra-abdominal desmoplastic small round-cell tumor.
Report of 19 cases of a distinctive type of high-grade polyphe-
notypic malignancy affecting young individuals. Am J Surg
Pathol 1991;15:499-513.
9. Ordi J, de Alava E, Torne A, Mellado b, Pardo-Mindan J, Igle-
sias X, Cardesa A. Intraabdominal desmoplastic small round
cell tumor with EWS/ERG fusion transcript. Am J Surg
Pathol 1998 ;8:1026-32.
10. Ordonez NG, el-Naggar AK, Ro JY, Silva EG, Mackay B. In-
traabdominal desmoplastic small cell tumor: a light microsco-
pic, immunocytochemical, ultrastructural, and flow cytome-
tric study. Hum Pathol 1993; 24: 850-865
11. La Quaglia MP, Brennan MF. The clinical approach to desmo-
plastic small round cell tumour. Surg Oncol 2000;9: 77-81
12. Frappaz D, Bouffet E, Dolbeau D,Bouvier R,Carrie C, Louis
D, Pondarre C, Tabone E, Phillip T, Brunat-Mentigny M. De-
smoplastic small round cell tumour of the abdomen. Cancer
1994;73:1753-1756
13. Bisogno G, Roganovich J, Sotti G, et al. Desmoplastic small
round cell tumor in children and adolescents. Med Pediatr
Oncol 2000;34:228–342.
14. Wolf AN, Ladanyi M, Paull G, et al. The expanding clinical
spectrum of desmoplastic small round cell tumor: a report of
two cases with molecular confirmation. Hum Pathol.
1999;30:430–435
15. Roganovich J, Bisogno G, Cecchetto G, D’Amore E, Carli M.
Paratesticular desmoplastic small round cell tumor: case report
and review of the literature. J Surg Oncol 1999;71:269-72.
16. Gil A, Gomez Portilla A, Brun EA, Sugarbaker PH. Clinical
perspective on desmoplastic small round-cell tumor. Oncology
2004; 67: 231-242.
17. Farhat F, Culine S, Lhomme C, Duvillard P, Soulie P, Michel
G, Terrier-Lacombe MJ, Theodore C, Schreinerova M, Droz
JP. Desmoplastic small round cell tumors: results of a four-
drug chemotherapy regimen in five adult patients. Cancer
1996; 77:1363-1366.
18. Kurre P, Felgenhauer JL, Miser JS, Patterson K, Hawkins DS.
Successful dose-intensive treatment of desmoplastic small
round cell tumor in three children. J Pediatr Haematol Oncol
2000; 22: 446-450
19. Bisogno G, Ferrari A, Bergeron C, Scagnellato A, Prete A,
Alaggio R, Casanova M, D’angelo P, Di Cataldo A, Carli M.
The IVADo Regimen. A pilot study with Ifosfamide, Vincri-
stine, Actinomycin D, and Doxorubicin in children with me-
tastaric soft tissue sarcoma. Cancer 2005;103:1719-24
20. Schmidt BF, Koscielniak E, PilzT, Treuner J. Radiation the-
rapy in juvenile aggressive fibromatosis. Klin Pediatr 1999;
211:296-9.
21. Baltogiannis N, Mavridis G, Keramidas D. Intraabdominal
desmoplastic small round cell tumour: report of two cases in
paediatric patients. Eur J Pediatr Surg 2002;12:333-6.
References
